Eg is halving the dose of canagliflozin and empagliflozin more effective than one pure strategy effective dose of each
[their activity is not EXACTLY identical]
Eg is halving the dose of canagliflozin and empagliflozin more effective than one pure strategy effective dose of each
[their activity is not EXACTLY identical]
Do they have different mechanisms of action?
yes, one is a sglt1 inhibitor and the second is an sglt2 inhibitor
Canagliflozin is also an SGLT2 inhibitor.
Both of these are SGLT2 inhibitors.
I think Alex is interested in finding out if adding some of the SGLT1 inhibition from canagliflozin will complement a pure SGLT2I such as empagliflozin, or is it just best to stick to one or the other.
I’d hazard a guess that most of the benefits come from SGLT2I, and I don’t really need the SGLT1I.
That is a bold guess…
… since the only ITP or other actual longevity studies and data are all with Cana / SGLT1, there are mechanistic reasons to think the gut effects (which you don’t get from just 2-inhibition) are important for longevity, and it’s only for SGLT1 that we have Mendelian Randomization data for mortality.
True. I could be wrong. However I do like the results for empagliflozin, so I’m going to give that a try first. As more data is available, it may change my mind.
My understanding is that cana inhibites both 1 and 2
Totally. Anything I said make it sound like I think otherwise?